CHEBI:81559 - resolvin E1

Main ChEBI Ontology Automatic Xrefs Reactions Pathways Models
ChEBI Name resolvin E1
ChEBI ID CHEBI:81559
Definition A resolvin that is (6Z,8E,10E,14Z,16E)-icosa-6,8,10,14,16-pentaenoic acid which is substituted at positions 5, 12 and 18 by hydroxy groups (the 5S,12R,18R stereoisomer).
Stars This entity has been manually annotated by the ChEBI Team.
Supplier Information ZINC000056875015
Download Molfile XML SDF
Formula C20H30O5
Net Charge 0
Average Mass 350.450
Monoisotopic Mass 350.20932
InChI InChI=1S/C20H30O5/c1-2-17(21)11-8-5-9-14-18(22)12-6-3-4-7-13-19(23)15-10-16-20(24)25/h3-9,11-13,17-19,21-23H,2,10,14-16H2,1H3,(H,24,25)/b4-3+,9-5-,11-8+,12-6+,13-7-/t17-,18+,19-/m1/s1
InChIKey AOPOCGPBAIARAV-OTBJXLELSA-N
SMILES C(\[C@H](CCCC(O)=O)O)=C\C=C\C=C\[C@@H](C\C=C/C=C/[C@@H](CC)O)O
Metabolite of Species Details
Homo sapiens (NCBI:txid9606) Found in blood (UBERON:0000178). See: PubMed
Homo sapiens (NCBI:txid9606) See: PubMed
Roles Classification
Chemical Role(s): Bronsted acid
A molecular entity capable of donating a hydron to an acceptor (Bronsted base).
(via oxoacid )
Biological Role(s): human xenobiotic metabolite
Any human metabolite produced by metabolism of a xenobiotic compound in humans.
specialised pro-resolving mediator
A class of cell signaling molecules enzymatically derived from n-3 long chain polyunsaturated fatty acids that have important roles in orchestrating the resolution of tissue inflammation.
(via resolvin )
Application(s): anti-inflammatory agent
Any compound that has anti-inflammatory effects.
specialised pro-resolving mediator
A class of cell signaling molecules enzymatically derived from n-3 long chain polyunsaturated fatty acids that have important roles in orchestrating the resolution of tissue inflammation.
(via resolvin )
View more via ChEBI Ontology
ChEBI Ontology
Outgoing resolvin E1 (CHEBI:81559) has role anti-inflammatory agent (CHEBI:67079)
resolvin E1 (CHEBI:81559) has role human xenobiotic metabolite (CHEBI:76967)
resolvin E1 (CHEBI:81559) is a hydroxy polyunsaturated fatty acid (CHEBI:140345)
resolvin E1 (CHEBI:81559) is a long-chain fatty acid (CHEBI:15904)
resolvin E1 (CHEBI:81559) is a nonclassic icosanoid (CHEBI:61703)
resolvin E1 (CHEBI:81559) is a resolvin (CHEBI:132120)
resolvin E1 (CHEBI:81559) is a triol (CHEBI:27136)
resolvin E1 (CHEBI:81559) is conjugate acid of resolvin E1(1−) (CHEBI:91000)
Incoming resolvin E1(1−) (CHEBI:91000) is conjugate base of resolvin E1 (CHEBI:81559)
IUPAC Name
(5S,6Z,8E,10E,12R,14Z,16E,18R)-5,12,18-trihydroxyicosa-6,8,10,14,16-pentaenoic acid
Synonyms Sources
(5S,12R,18R)-trihydroxy-(6Z,8E,10E,14Z,16E)-eicosapentaenoic acid ChEBI
(5S,12R,18R)-trihydroxy-(6Z,8E,10E,14Z,16E)-icosapentaenoic acid ChEBI
(6Z,8E,10E,14Z,16E)-5,12,18-trihydroxyicosa-6,8,10,14,16-pentaenoic acid HMDB
5S,12R,18R-Trihydroxy-6Z,8E,10E,14Z,16E-eicosapentaenoic acid KEGG COMPOUND
5S,12R,18R-trihydroxy-6Z,8E,10E,14Z,16E-eicosapentaenoic acid LIPID MAPS
5S,12R,18R-Trihydroxy-6Z,8E,10E,14Z,16E-EPA HMDB
ResolvinE1 HMDB
RvE1 HMDB
Manual Xrefs Databases
C18171 KEGG COMPOUND
CPD66-57 MetaCyc
HMDB0010410 HMDB
LMFA03070019 LIPID MAPS
View more database links
Registry Number Type Source
11884203 Reaxys Registry Number Reaxys
Citations Waiting for Citations Types Sources
15753205 PubMed citation Europe PMC
16112645 PubMed citation Europe PMC
16373400 PubMed citation Europe PMC
16757471 PubMed citation Europe PMC
17131464 PubMed citation Europe PMC
17339491 PubMed citation Europe PMC
17982093 PubMed citation Europe PMC
18190790 PubMed citation Europe PMC
18292578 PubMed citation Europe PMC
18480426 PubMed citation Europe PMC
19368495 PubMed citation Europe PMC
20119897 PubMed citation Europe PMC
20708601 PubMed citation Europe PMC
22257864 PubMed citation Europe PMC
22297737 PubMed citation Europe PMC
22336459 PubMed citation Europe PMC
22951188 PubMed citation Europe PMC
24344649 PubMed citation Europe PMC
25637017 PubMed citation Europe PMC
25681756 PubMed citation Europe PMC
25792445 PubMed citation Europe PMC
26438363 PubMed citation Europe PMC
Last Modified
05 March 2018